V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012561 | 330005986 | null | 101 | Disease modification (D) | 2016-08-19 | 2017-07-27 | IVA | 02 | N | 330000507 | AML19 TRIAL |
| 330012562 | 330006007 | null | 80 | Palliative (P) | 2015-04-01 | 2015-04-01 | Dacarbazine | N | null | 330004663 | CAPECITABINE + CARBOPLATIN + RT |
| 330012563 | 330006012 | 1.65 | 66.7 | Curative (C) | 2017-09-27 | 2017-10-04 | GEMCITABINE | N | N | 330004965 | DOXORUBICIN + METHOTREXATE |
| 330012564 | 330006016 | 0 | 97.6 | Adjuvant (A) | null | 2018-12-05 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | 330005236 | UKALL XII |
| 330012565 | 330006018 | null | 96 | Palliative (P) | 2019-06-12 | 2019-06-17 | Hydroxycarbamide | N | null | 330005707 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330012566 | 330009279 | 1.74 | 68.999 | Palliative (P) | 2018-08-17 | 2018-08-21 | AML 19 TRIAL | N | N | 330006301 | CAPECITABINE + GEMCITABINE |
| 330012567 | 330006022 | 1.57 | 52 | Palliative (P) | 2015-11-30 | 2016-02-01 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | null | 330006361 | FCR |
| 330012568 | 330009284 | 1.72 | 97.6 | Neo-adjuvant (N) | 2019-02-07 | 2019-06-02 | R Chlorambucil | N | N | 330006782 | CARBOPLATIN + VINCRISTINE |
| 330012569 | 330006033 | 1.72 | null | Neo-adjuvant (N) | 2018-07-03 | 2018-07-03 | AML 18 TRIAL | N | N | 330007632 | CAPECITABINE + CISPLATIN |
| 330012570 | 330006046 | 0.9 | 87.3 | Adjuvant (A) | 2018-05-05 | 2018-09-02 | Cisplatin + Fluorouracil + RT 5day | N | N | 330009579 | CAPECITABINE + VINORELBINE |
| 330012571 | 330006056 | null | 108 | Curative (C) | 2018-11-19 | 2019-06-01 | Hydroxycarbamide | null | null | 330010132 | PEMBROLIZUMAB |
| 330012572 | 330006060 | 1.84 | 79.7 | null | 2017-08-26 | 2017-08-27 | VIDE | 02 | N | 330010514 | STREPTOZOCIN |
| 330012573 | 330006064 | 0 | 9.3 | Palliative (P) | 2015-05-15 | 2015-05-15 | Capecitabine + Streptozocin | 2 | N | 330010809 | TRASTUZUMAB |
| 330012574 | 330006069 | 1.71 | 97.15 | Palliative (P) | 2018-09-28 | 2018-09-28 | AML 19 TRIAL | N | N | 330011080 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330012575 | 330006079 | 1.91 | 42.2 | Palliative (P) | 2015-10-22 | 2015-10-27 | CYCLOPHOSPHAMIDE | N | N | 330012831 | IPO |
| 330012576 | 330009314 | 1.98 | 49.4 | Palliative (P) | 2020-01-07 | 2020-01-11 | CHOP R | N | N | 330015148 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330012577 | 330011072 | 1.58 | null | Palliative (P) | 2016-02-11 | 2016-02-14 | PEMBROLIZUMAB | N | null | 330015218 | FLAG |
| 330012578 | 330006089 | 1.7 | null | Palliative (P) | 2017-04-15 | 2017-07-15 | VINCRISTINE | Y | N | 330015310 | UKALL2014 |
| 330012579 | 330009319 | 1.23 | 73.85 | Curative (C) | 2017-03-03 | 2017-03-06 | Sunitinib | 02 | N | 330015685 | CARBOPLATIN + VINCRISTINE |
| 330012580 | 330006099 | 1.69 | 80.6 | Curative (C) | 2014-09-30 | 2014-09-30 | Cytarabine Low Dose | 02 | N | 330016127 | CARBO + THIOTEPA + TOPOTECAN |
| 330012581 | 330012584 | null | 67.9 | Palliative (P) | 2014-12-27 | 2014-12-28 | Temozolomide + RT | N | null | 330016564 | TRIPLE INTRATHECAL |
| 330012582 | 330011084 | 1.57 | 124.5 | Palliative (P) | 2018-05-27 | 2018-05-29 | Carboplatin + Cetux + FU (>Cycle 2) | N | N | 330020339 | AML19 TRIAL |
| 330012583 | 330006122 | 0 | 103.3 | Curative (C) | null | 2017-11-28 | AML 18 TRIAL | N | N | 330020858 | DOXORUBICIN + OLARATUMAB |
| 330012584 | 330006129 | 1.93 | 90.7 | Curative (C) | null | 2017-07-09 | Mitoxantrone | null | N | 330021091 | CARBOPLATIN + DOCETAXEL |
| 330012585 | 330006131 | 1.68 | 49.4 | Disease modification (D) | 2018-10-06 | 2018-10-18 | Cisplatin + Pemetrexed | N | N | 330021332 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330012586 | 330013101 | 1.6 | 53 | Palliative (P) | 2018-08-29 | 2018-09-03 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | N | 330021404 | CARBOPLATIN + DOXORUBICIN |
| 330012587 | 330006144 | 1.73 | 62.2 | Disease modification (D) | 2016-06-09 | 2016-07-04 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | Y | 330024623 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330012588 | 330006148 | null | null | Palliative (P) | 2017-01-23 | 2017-02-05 | ICE + GCSF | 02 | N | 330025015 | CYTARABINE |
| 330012589 | 330006153 | 1.58 | null | Curative (C) | 2017-08-08 | 2017-08-29 | AXITINIB | N | N | 330007206 | BEVACIZUMAB |
| 330012590 | 330006159 | 1.61 | 8.6 | null | 2019-01-13 | 2019-02-28 | Triple / Double Intrathecal Therapy | N | null | 330009579 | PONATINIB |
| 330012591 | 330010128 | null | 19.9 | Curative (C) | 2015-11-09 | 2016-07-30 | CNS LGG2004 03 vinc + carbo | Y | N | 330000004 | NOT MATCHED |
| 330012592 | 330002937 | 0 | null | Palliative (P) | 2014-05-26 | 2014-05-27 | CNS GCT II Germinoma - Ifos Etop | 02 | null | 330000050 | NOT MATCHED |
| 330012594 | 330002952 | 0 | 20.6 | Curative (C) | 2018-07-21 | 2018-07-22 | NB HRNBL-1 COJEC Ind COURSE B | N | N | 330000081 | NOT MATCHED |
| 330012595 | 330007587 | 0 | 33 | Curative (C) | 2016-01-19 | 2018-12-30 | EW Rel rEECur Gemcitabine/Docetaxel | N | N | 330000144 | NOT MATCHED |
| 330012596 | 330002972 | 0 | 79.1 | Adjuvant (A) | 2016-11-14 | 2017-05-14 | WT SIOP 2002 01 post op Carbo, Etop | 01 | N | 330000172 | NOT MATCHED |
| 330012597 | 330002984 | null | null | Curative (C) | 2014-07-18 | 2015-01-17 | EW EuroEwing 2012 Arm B VC | Y | N | 330000242 | NOT MATCHED |
| 330012598 | 330002989 | 0 | 8 | Disease modification (D) | 2016-08-08 | 2017-05-24 | NB HRNBL-1 COJEC Ind COURSE B | Y | null | 330000247 | NOT MATCHED |
| 330012599 | 330002994 | 1.85 | 16.8 | Disease modification (D) | 2018-02-01 | 2018-02-08 | CNS LGG 2004 03 con vinc +cisplatin | Y | null | 330000263 | NOT MATCHED |
| 330012600 | 330003000 | null | 9.8 | Palliative (P) | 2017-06-17 | 2018-01-12 | NB HRNBL-1 BUMEL MAT | N | N | 330000299 | NOT MATCHED |
| 330012601 | 330011547 | null | 9.7 | Curative (C) | 2014-11-17 | 2015-02-02 | Mitotane + STREPTOZOCIN | N | N | 330000305 | NOT MATCHED |
| 330012602 | 330003006 | 1.81 | 11.5 | Curative (C) | 2017-11-11 | 2018-02-10 | NB Low/Interm risk guidelines Carbo/Etop | 2 | Y | 330000334 | NOT MATCHED |
| 330012603 | 330003010 | null | 56.2 | Curative (C) | 2015-12-05 | 2016-08-13 | NB HRNBL-1 ch14.18/CHO(trial) +IL-2 | null | null | 330000353 | NOT MATCHED |
| 330012604 | 330003014 | 1.23 | 9 | Curative (C) | 2017-11-22 | 2017-11-23 | NB HRNBL-1 COJEC Ind COURSE B | N | null | 330000390 | NOT MATCHED |
| 330012605 | 330003029 | null | null | Curative (C) | 2014-11-23 | 2015-05-21 | Cisplatin + Radiotherapy | N | null | 330000410 | CISPLATIN + RT |
| 330012606 | 330011554 | 1.66 | 98.4 | Curative (C) | 2016-04-14 | 2016-04-14 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 330000450 | CISPLATIN + RT |
| 330012607 | 330007621 | null | 103.3 | Adjuvant (A) | 2013-07-06 | 2013-08-12 | null | N | N | 330000516 | NOT MATCHED |
| 330012608 | 330003053 | null | 0 | Curative (C) | 2012-07-16 | 2014-02-21 | NB HRNBL-1 COJEC Ind COURSE B | Y | Y | 330000542 | NOT MATCHED |
| 330012609 | 330003067 | 1.71 | 46.1 | Adjuvant (A) | 2017-03-25 | 2018-08-20 | CISPLATIN + RT | null | Y | 330000642 | CISPLATIN + RT |
| 330012610 | 330003109 | 1.71 | 16.4 | Curative (C) | 2014-02-13 | 2014-02-26 | NB HRNBL-1 COJEC Ind COURSE C | null | N | 330000894 | NOT MATCHED |
| 330012611 | 330003178 | 1.54 | 103.9 | Curative (C) | 2015-12-11 | 2016-09-07 | CISPLATIN + RT | 2 | N | 330001442 | CISPLATIN + RT |